Product Images Gabapentin

This appears to be a table or a chart showing mean pain scores for various treatments over a period of time. The treatments include placebo and gabapentin at a dose of 3600mg/day. The chart also shows a baseline score and scores from weeks 1 to 8 during the fixed-dose period. The text does not provide more information, such as the condition being treated or the method of evaluation, making it difficult to interpret the results.*

This is a clinical trial report showing the mean pain score for a group of participants who underwent a 3-week dose titration period followed by a 4-week fixed dose period. The group was split into three sub-groups: the placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The results suggest that gabapentin was effective in reducing pain as compared to the placebo, and a higher dose (2400 mg/day) was associated with even greater pain reduction. The statistical significance was noted at p<0.01. The report does not provide any further information.*

The text shows a chart of the percentage of responders at endpoint for two studies. The chart indicates that the responders for the GBP treatment were significantly greater than placebo (PBO) in both studies, according to the legend. The data for Study 1 shows a 45% response rate for the GBP treatment and a 20% response rate for the placebo. The data for Study 2 shows a 35% response rate for the GBP treatment and a 15% response rate for the placebo. The chart also displays numbers such as 4@, 14%, 12%, 5 that may have been inaccurately recognized by the .*

This is a medicine container labeled with the product information. The medicine contains Gabapentin 300mg in the form of 90 capsules. The Lot number is SAMPLE and the expiration date is 00/00.*

This text appears to be a medical description of patients' clinical laboratory test results. It includes parameters such as age, weight, creatinine levels, and CLCr (creatinine clearance). However, because the text is missing important information and contains errors related to special characters and formatting, it is difficult to interpret and provide a more detailed description.*